Pathway
Indication, sequence, target product profile and development scenarios.
VED DECISION LAB
Make the decision that changes programme value
A senior-led working model for consequential clinical, regulatory and evidence decisions—from first-in-human strategy through registrational readiness.
VED working method
- 01Question
- 02Evidence
- 03Action
01
THE PROBLEM
Development teams rarely need more slides
They need a defensible choice that reconciles science, regulatory precedent, operational reality, capital and time. VED frames the actual decision, tests the assumptions and leaves named owners with an executable next step.
Trial
Population, comparator, endpoints, dose, expansion and evidence trade-offs.
Regulatory
US, EU, UK and global positions, interaction strategy and submission path.
Precision
Biomarkers, diagnostics, assay context, samples and data dependencies.
Readiness
Cross-functional gaps, critical path, governance and 90-day ownership.
Diligence
Independent programme review for boards, investors and transaction teams.
02
WAYS TO ENGAGE
A focused sprint or embedded leadership
FIXED SPRINT
Programme Decision Sprint
Resolve one high-value programme question in ten business days.
Explore INTERACTIONHealth-Authority Sprint
Build the position and team around an FDA, EMA or MHRA interaction.
Explore EMBEDDEDFractional R&D Leadership
Put senior accountability into the programme for a defined period.
Explore03
FOCUS
Where VED has the strongest right to win
- Oncology and immuno-oncology, including dose optimisation and expansion strategy
- Biologics, bispecifics, cell and gene therapy and other advanced modalities
- Precision medicine, biomarkers and companion-diagnostic interfaces
- FDA, EMA and MHRA strategy that must remain globally coherent
- Lean teams moving from early clinical evidence toward registrational development
Start with the constraint
What must your programme decide, prove or deliver next?
Share the situation, evidence and timing. We will propose the smallest credible first step.